Arcosa shareholders have officially approved the acquisition by CRH for $150 per share in an all-cash transaction. This marks a significant step towards the completion of the merger, which is expected in Q1 2027, pending regulatory approvals.
Arcosa, Inc. announced that its shareholders have approved the acquisition by CRH for $150 per share in an all-cash transaction. This approval is a critical milestone in the merger process, confirming shareholder support for the deal. It matters because it significantly de-risks the transaction for Arcosa shareholders, who are now assured of the $150 cash payout, assuming regulatory approvals are met. For CRH, it signifies progress in its strategic expansion. The short-term implication for Arcosa (ACA) is that its stock price will likely trade very close to the $150 acquisition price, minus any discount for the time value of money and remaining regulatory risk. For CRH (CRH), the impact is more neutral as the acquisition was previously announced and priced in. A key opportunity for traders is to monitor the spread between ACA's current price and $150, looking for arbitrage opportunities, while the main risk remains potential regulatory hurdles delaying or derailing the Q1 2027 closing.